WASHINGTON, D.C. - John F. Crowley, President and CEO of the Biotechnology Innovation Organization (BIO), released the following statement regarding today’s dismissal of the voting members of the CDC Advisory Committee on Immunization Practices:   “The Advisory Committee on Immunization Practices (ACIP) is vital to ensuring scientific rigor and third-party experts inform decisions about the safe and effective use of vaccines in the US. Under the law, ACIP also plays a critical role determining how the American people access immunizations.  We are greatly concerned about the uncertainty created by the abrupt dismissal of the serving committee members and the loss of years of experience, especially less than three weeks before the next ACIP meeting, with consequential votes on recommendations that will affect Americans’ access to RSV, flu, HPV and other important vaccines. While the advisors serve on the ACIP at the selection and appointment by the Secretary, the removal of committee members will cause significant disruption in this critical process. Immunization reviews take place through working groups over many months, culminating with discussion during a public meeting. A wholesale change of this manner will negatively affect the Committee’s ability to deliberate and make well-informed recommendations, putting American lives at risk.   We agree that transparency is key to restoring trust in immunizations; however, the actions taken today upend a time-tested system that has protected American public health.”  ### 

BIO to Transition Agricultural and Environmental Biotech Workstreams  Key Senior Hires Bolster Focus on Regulatory Affairs, Emerging Companies   and Economic Growth   Washington, DC, May 28, 2025 – The Biotechnology Innovation Organization (BIO) today announced plans to dedicate its focus entirely to human health and to transition the work of its Agriculture and Environment (A&E) section to other organizations.  This change is intended to enable an enhanced strategic focus on each of these respective areas of biotechnology and will be effective July 1, 2025. In support of this transition, BIO announced the hiring of two new senior executives to lead Regulatory Affairs and a new “Center of Excellence” focused on Emerging Companies & Economic Growth.   “The field of biotechnology is increasingly diverse, with great threats and significant opportunities,” said John F. Crowley, President and CEO, BIO. “In consultation with the BIO Executive Committee and the Agriculture and Environment Governing Board, BIO has determined that these organizational changes will enable greater focus and impact on behalf of our healthcare members, and will sharpen our advocacy work on critical policy priorities for the improvement of human health – modernizing the FDA’s regulatory processes; building back a robust biopharmaceutical manufacturing base across the US and our allies; preserving strong IP protections; fostering capital formation; protecting our national security; and enabling 21st Century access to medicines. At the same time, this change will enable A&E member companies to enhance their focus on agricultural and environmental biotech at expert third-party organizations.”   BIO also announced the addition of two new senior leaders to its healthcare team.   Annetta Beauregard will join BIO effective June 9, 2025 as SVP, Science & Regulatory Affairs, where she will spearhead BIO’s regulatory policy strategy and…